Your browser is no longer supported. Please, upgrade your browser.
AGE AgeX Therapeutics, Inc. daily Stock Chart
AgeX Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.29 Insider Own0.20% Shs Outstand38.22M Perf Week26.77%
Market Cap150.20M Forward P/E- EPS next Y- Insider Trans- Shs Float21.22M Perf Month43.43%
Income-10.40M PEG- EPS next Q- Inst Own23.60% Short Float4.27% Perf Quarter-2.00%
Sales1.50M P/S100.14 EPS this Y-17.00% Inst Trans11.41% Short Ratio11.39 Perf Half Y57.83%
Book/sh0.26 P/B15.12 EPS next Y- ROA-85.50% Target Price- Perf Year-
Cash/sh0.23 P/C17.47 EPS next 5Y- ROE-109.80% 52W Range1.13 - 5.95 Perf YTD31.44%
Dividend- P/FCF- EPS past 5Y- ROI-149.90% 52W High-33.95% Beta-
Dividend %- Quick Ratio4.20 Sales past 5Y- Gross Margin79.40% 52W Low247.79% ATR0.30
Employees12 Current Ratio4.20 Sales Q/Q100.00% Oper. Margin- RSI (14)62.54 Volatility9.70% 8.59%
OptionableNo Debt/Eq0.01 EPS Q/Q- Profit Margin- Rel Volume0.91 Prev Close3.83
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume79.55K Price3.93
Recom- SMA2030.48% SMA504.00% SMA200-0.61% Volume72,088 Change2.61%
May-15-19 04:05PM  AgeX Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update Business Wire -5.20%
May-01-19 08:00AM  AgeX Therapeutics to Participate at Biotech Investing in Longevity from Aikora Health and Foresight Institute Business Wire
Apr-05-19 08:00AM  AgeX Therapeutics to Present at Master Investor Show 2019 Business Wire +13.88%
Apr-01-19 04:48PM  AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update Business Wire
Mar-22-19 07:00AM  AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants Business Wire
Mar-21-19 07:00AM  AgeX Therapeutics to Present at Undoing Aging 2019, March 28-30 in Berlin, Germany Business Wire
Mar-07-19 07:00AM  LifeMap Sciences and iCarbonX Research Shenzhen Announce Strategic Collaboration Business Wire
Feb-14-19 08:00AM  BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias GlobeNewswire +5.37%
Jan-31-19 08:00AM  AgeX Therapeutics to Present at Longevity Leaders Conference, February 4 in London Business Wire
Jan-22-19 08:00AM  AgeX Therapeutics CEO Dr. Michael D. West Presents at Precision Medicine World Conference 2019 Business Wire -10.40%
Jan-10-19 08:00AM  LifeMap Sciences, Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market Business Wire +21.61%
Jan-09-19 08:00AM  AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity Business Wire
Jan-04-19 08:00AM  BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase GlobeNewswire +13.83%
Jan-02-19 07:00AM  AgeX Therapeutics to Present at Biotech Showcase 2019 Business Wire
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of cellular and regenerative therapeutics for diseases of old age in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. was founded in 2017 and is based in Alameda, California.